— Know what they know.
Not Investment Advice
Also trades as: 0HTG.L (LSE) · $vol 0M

CAH NYSE

Cardinal Health, Inc.
1W: +3.9% 1M: -7.0% 3M: -3.9% YTD: +10.9% 1Y: +44.5% 3Y: +169.6% 5Y: +393.6%
$228.30
-1.79 (-0.78%)
 
Weekly Expected Move ±3.1%
$214 $221 $228 $235 $242
NYSE · Healthcare · Medical - Distribution · Tech Score Neutral · Power 55 · $53.5B mcap · 234M float · 0.893% daily turnover · Short 51% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NARROW EDGE
57.3 / 100
NoneWeakNarrowWide
Primary source: Efficient Scale  ·  ROIC: 92.8%
Cost Advantage
64
Intangibles
41
Switching Cost
50
Network Effect
65
Scale ★
80
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. CAH has a Narrow competitive edge (57.3/100) — meaningful but not impregnable advantages over competitors. The primary source of advantage is Efficient Scale. ROIC of 92.8% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$250
Low
$273
Avg Target
$292
High
Based on 9 analysts since Aug 11, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 18Hold: 15Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$273.30
Analysts10
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-08-19 RBC Capital Ryan Halsted Initiated $276 — +17.5% $234.98
2026-08-13 Barclays — $258 $275 +17 +17.4% $234.16
2026-08-12 Morgan Stanley — $255 $265 +10 +12.0% $236.63
2026-08-12 Evercore ISI — $240 $270 +30 +12.4% $240.26
2026-08-12 UBS — $274 $280 +6 +16.5% $240.26
2026-08-12 Wells Fargo Stephen Baxter $256 $277 +21 +15.3% $240.26
2026-08-12 Mizuho Securities Steven Valiquette $235 $250 +15 +4.1% $240.26
2026-08-12 Robert W. Baird Eric Coldwell $248 $274 +26 +14.0% $240.26
2026-08-11 Leerink Partners — $275 $292 +17 +21.5% $240.26
2026-07-20 UBS — $260 $274 +14 +21.0% $226.42
2026-05-01 Robert W. Baird — $252 $248 -4 +27.1% $195.08
2026-04-08 Evercore ISI Elizabeth Anderson $260 $240 -20 +11.6% $215.13
2026-03-09 Leerink Partners Michael Cherny $240 $275 +35 +23.7% $222.28
2026-02-24 Barclays — $243 $258 +15 +14.8% $224.82
2026-02-10 Wells Fargo — $179 $256 +77 +13.4% $225.76
2026-02-06 Morgan Stanley — $245 $255 +10 +11.0% $229.63
2026-02-06 Robert W. Baird — $250 $252 +2 +10.1% $228.78
2026-02-06 UBS Kevin Caliendo $220 $260 +40 +13.7% $228.63
2026-02-06 Mizuho Securities Steven Valiquette $222 $235 +13 +3.4% $227.18
2026-02-05 Evercore ISI Elizabeth Anderson $220 $260 +40 +14.4% $227.18
2026-01-29 Morgan Stanley Erin Wright $181 $245 +64 +16.5% $210.39
2026-01-14 Robert W. Baird Eric Coldwell $232 $250 +18 +17.9% $211.97
2026-01-13 Leerink Partners Michael Cherny $186 $240 +54 +15.3% $208.24
2026-01-12 Mizuho Securities Steven Valiquette $210 $222 +12 +10.4% $201.11
2025-12-08 Barclays Glen Santangelo $63 $243 +180 +22.2% $198.88
2025-11-03 Mizuho Securities Steven Valiquette $110 $210 +100 +10.4% $190.22
2025-11-03 Jefferies — $150 $220 +70 +15.7% $190.22
2025-10-31 Evercore ISI Elizabeth Anderson $115 $220 +105 +15.0% $191.29
2025-10-31 UBS — $78 $220 +142 +14.5% $192.07
2025-10-31 Robert W. Baird — $140 $232 +92 +20.6% $192.36
2025-08-22 Argus Research — $148 $189 +41 +27.6% $148.10
2025-08-12 Leerink Partners Michael Cherny Initiated $186 — +27.1% $146.30
2025-08-11 Jefferies Brian Tanquilut Initiated $150 — -4.9% $157.66
2025-06-13 Morgan Stanley Erin Wright $119 $181 +62 +12.1% $161.41
2025-06-03 Wells Fargo Stephen Baxter $101 $179 +78 +15.1% $155.48
2025-02-04 Argus Research Kristina Ruggeri $125 $148 +23 +18.2% $125.17
2024-09-23 Robert W. Baird Eric Coldwell $137 $140 +3 +24.7% $112.30
2024-09-11 Argus Research David Toung $115 $125 +10 +11.2% $112.36
2024-08-16 Deutsche Bank George Hill $51 $119 +68 +10.3% $107.91
2024-08-15 Evercore ISI Elizabeth Anderson $68 $115 +47 +6.8% $107.71
2024-08-15 Morgan Stanley Erin Wright $90 $119 +29 +11.9% $106.36
2024-08-15 Mizuho Securities Ann Hynes Initiated $110 — +2.4% $107.39
2024-08-15 Robert W. Baird Eric Coldwell $129 $137 +8 +27.6% $107.33
2024-08-15 Wells Fargo Stephen Baxter Initiated $101 — -5.0% $106.36
2024-06-11 CFRA Garrett Nelson Initiated $111 — +12.1% $99.01
2024-05-29 Robert W. Baird Eric Coldwell $128 $129 +1 +36.1% $94.75
2024-05-15 Argus Research David Toung Initiated $115 — +18.0% $97.43
2024-05-03 Robert W. Baird Eric Coldwell $134 $128 -6 +24.3% $102.98
2024-04-05 Robert W. Baird Eric Coldwell $94 $134 +40 +21.7% $110.12
2023-08-14 Morgan Stanley Erin Wright $86 $90 +4 -3.2% $92.99

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B-
Oct 02, 2026
DCF
5
ROE
1
ROA
5
D/E
1
P/E
2
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. CAH receives an overall rating of B-. Strongest factors: DCF (5/5), ROA (5/5). Areas of concern: ROE (1/5), D/E (1/5), P/E (2/5), P/B (1/5).
Rating Change History
DateFromTo
2026-10-01 C+ B-
2026-08-13 C C+
2026-08-12 C- C
2026-08-11 C C-
2026-08-10 C+ C
2026-04-22 B- C+
2026-04-01 C+ B-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 59 Grade C
Profitability
6
Balance Sheet
42
Earnings Quality
82
Growth
68
Value
41
Momentum
84
Safety
100
Cash Flow
65
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. CAH scores highest in Safety (100/100) and lowest in Profitability (6/100). A grade of C represents mixed fundamentals — strengths in some areas offset by weaknesses.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
5.09
Safe Zone
Piotroski F-Score
8/9
✓ ✓ ✓ ✓ ✓ ✗ ✓ ✓ ✓
Beneish M-Score
-2.80
Unlikely Manipulator
Ohlson O-Score
-6.84
Bankruptcy prob: 0.1%
Low Risk
Credit Rating
B-
Score: 20.0/100
Trend: Stable
Earnings Quality
75/100
OCF/NI: 3.02x
Accruals: -6.3%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. CAH scores 5.09, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. CAH scores 8/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. CAH's score of -2.80 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. CAH's implied 0.1% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. CAH receives an estimated rating of B- (score: 20.0/100), with a stable trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). CAH's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
31.40x
PEG
2.54x
P/S
0.21x
P/B
-18.69x
P/FCF
12.42x
P/OCF
10.86x
EV/EBITDA
17.62x
EV/Revenue
0.24x
EV/EBIT
24.29x
EV/FCF
13.54x
Earnings Yield
3.05%
FCF Yield
8.05%
Shareholder Yield
3.29%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 31.4x earnings, CAH commands a growth premium.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.788
NI / EBT
×
Interest Burden
0.862
EBT / EBIT
×
EBIT Margin
0.010
EBIT / Rev
×
Asset Turnover
4.605
Rev / Assets
×
Equity Multiplier
-19.495
Assets / Equity
=
ROE
-60.5%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. CAH's ROE of -60.5% is driven by Asset Turnover (4.605), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
15.00%
Fair P/E
38.50x
Intrinsic Value
$278.43
Price/Value
0.85x
Margin of Safety
14.87%
Premium
-14.87%
Assessment
Neutral
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with CAH's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. CAH actually compounded EPS at 91.6% over three years; the model uses 15%, the highest rate it will extrapolate — of 4,457 company-quarters that grew faster than 200%, none sustained it over the following seven years. CAH trades at a -15% premium to its adjusted intrinsic value of $278.43, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 38.5x compares to the current market P/E of 31.4x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$228.23
Median 1Y
$283.67
5th Pctile
$175.95
95th Pctile
$456.85
Ann. Volatility
29.0%
Analyst Target
$273.30
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Jason M. Hollar
Chief Executive Officer
$1,500,000 $16,259,918 $22,574,349
Aaron E. Alt
Chief Financial Officer
$896,233 $4,318,999 $6,860,173
Deborah L. Weitzman
Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment
$770,479 $4,064,943 $6,120,157
Jessica L. Mayer
Chief Legal and Compliance Officer
$741,233 $3,556,822 $5,534,183
Stephen M. Mason
Chief Executive Officer, Global Medical Products and Distribution Segment
$761,986 $3,404,479 $5,293,365

CEO Pay Ratio

235:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $22,574,349
Avg Employee Cost (SGA/emp): $95,962
Employees: 63,900

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
63,900
+10.8% YoY
Revenue / Employee
$3,978,842
Rev: $254,248,000,000
Profit / Employee
$26,823
NI: $1,714,000,000
SGA / Employee
$95,962
Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
ROE 80.6% 37.4% -1.7% -1.7% 5.6% 2.1% -31.7% -14.2% -5.3% -22.5% -20.2% -27.6% -37.9% -40.8% -50.2% -52.1% -51.8% -56.7% -53.9% -60.5% -60.52%
ROA 2.7% 1.3% -2.2% -2.1% -2.5% -2.9% 1.1% 0.6% 0.3% 1.4% 1.2% 1.9% 3.0% 2.8% 3.3% 3.2% 3.2% 3.2% 2.9% 3.1% 3.10%
ROIC 27.7% 2.3% -14.5% -1.2% 115.1% 5.6% -40.3% -16.1% -6.1% -20.1% -51.6% -32.3% -1.4% 1.7% 1.2% 63.2% 1.1% 55.4% 83.2% 92.8% 92.77%
ROCE 9.3% 0.8% -3.5% -4.7% -7.6% -0.6% 5.5% 7.6% 6.5% 14.4% 10.3% 13.1% 22.1% 16.0% 17.0% 16.3% 16.2% 16.4% 14.8% 18.8% 18.83%
Gross Margin 3.7% 3.6% 3.8% 3.4% 3.3% 3.2% 3.5% 3.4% 3.2% 3.2% 3.5% 3.1% 3.6% 3.5% 3.9% 3.7% 3.6% 3.4% 4.1% 4.3% 4.30%
Operating Margin 0.9% -2.1% -0.2% 0.1% 0.3% -0.2% 1.1% 0.3% -0.1% 0.9% 0.7% 0.7% 1.1% 1.0% 1.3% 0.7% 1.0% 1.1% 0.8% 1.1% 1.14%
Net Margin 0.6% 0.1% -3.1% 0.3% 0.2% -0.3% 0.7% -0.1% -0.0% 0.6% 0.5% 0.4% 0.8% 0.7% 0.9% 0.4% 0.7% 0.7% 0.7% 0.6% 0.62%
EBITDA Margin 1.3% -1.7% 0.2% 0.4% 0.6% 0.1% 1.5% 0.6% 0.3% 1.2% 1.0% 1.0% 1.4% 1.3% 1.7% 1.1% 1.4% 1.1% 1.2% 1.8% 1.75%
FCF Margin 0.7% 0.7% 0.3% 1.5% 1.8% 1.4% 2.3% 1.2% 1.4% 1.6% 0.9% 1.4% 0.5% -0.2% 1.1% 0.8% 1.9% 2.3% 1.8% 1.8% 1.78%
OCF Margin 0.9% 0.9% 0.4% 1.7% 2.0% 1.7% 2.5% 1.4% 1.6% 1.8% 1.2% 1.7% 0.7% 0.0% 1.3% 1.1% 2.1% 2.5% 2.0% 2.0% 2.04%
ROA 3Y Avg snapshot only 2.61%
ROIC Economic snapshot only 92.77%
Cash ROA snapshot only 9.03%
Cash ROIC snapshot only 2.34%
CROIC snapshot only 2.05%
NOPAT Margin snapshot only 0.81%
Pretax Margin snapshot only 0.86%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 2.41%
SBC / Revenue snapshot only 0.14%
Valuation
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
P/E Ratio 11.48 24.00 -15.17 -14.45 -15.72 -14.98 40.24 88.49 150.14 37.83 48.40 27.57 20.74 21.58 21.10 25.67 23.44 29.16 31.91 32.78 31.403
P/S Ratio 0.08 0.08 0.08 0.07 0.09 0.10 0.09 0.11 0.10 0.11 0.12 0.10 0.12 0.13 0.15 0.18 0.16 0.20 0.20 0.22 0.210
P/B Ratio 9.36 13.35 -20.77 -19.00 -9.65 -8.61 -8.39 -7.81 -5.98 -6.99 -8.20 -7.32 -8.11 -9.47 -11.15 -14.41 -12.99 -16.85 -17.57 -19.49 -18.688
P/FCF 11.60 11.85 32.46 4.92 5.05 6.83 4.10 9.79 7.35 7.10 13.36 7.25 24.76 -57.70 13.48 21.66 8.40 8.82 11.33 12.42 12.415
P/OCF 8.61 8.93 18.21 4.31 4.53 5.97 3.75 8.14 6.24 6.14 10.55 6.26 16.80 9443.79 11.15 16.71 7.45 7.96 9.93 10.86 10.858
EV/EBITDA 7.13 18.99 77.10 202.19 -95.28 32.76 14.95 17.00 17.27 12.84 17.12 12.28 11.23 12.27 12.34 14.66 12.82 16.97 18.09 17.62 17.617
EV/Revenue 0.10 0.09 0.10 0.08 0.10 0.11 0.10 0.12 0.10 0.11 0.13 0.11 0.13 0.14 0.17 0.20 0.18 0.22 0.22 0.24 0.241
EV/EBIT 10.60 130.59 -38.30 -23.48 -21.21 -295.27 32.24 33.10 38.53 20.36 29.25 19.29 15.61 17.08 16.54 19.66 17.28 22.69 25.21 24.29 24.294
EV/FCF 14.43 14.06 39.76 5.32 5.57 7.40 4.26 10.26 7.64 7.14 14.43 7.39 26.91 -65.43 15.26 24.61 9.40 9.96 12.46 13.54 13.540
Earnings Yield 8.7% 4.2% -6.6% -6.9% -6.4% -6.7% 2.5% 1.1% 0.7% 2.6% 2.1% 3.6% 4.8% 4.6% 4.7% 3.9% 4.3% 3.4% 3.1% 3.1% 3.05%
FCF Yield 8.6% 8.4% 3.1% 20.3% 19.8% 14.6% 24.4% 10.2% 13.6% 14.1% 7.5% 13.8% 4.0% -1.7% 7.4% 4.6% 11.9% 11.3% 8.8% 8.1% 8.05%
PEG Ratio snapshot only 2.540
EV/OCF snapshot only 11.842
EV/Gross Profit snapshot only 6.269
Acquirers Multiple snapshot only 23.448
Shareholder Yield snapshot only 3.29%
Leverage & Solvency
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Current Ratio 1.12 1.15 1.08 1.08 1.04 1.04 1.03 1.00 0.99 0.98 0.98 0.98 0.95 1.02 0.94 0.94 0.96 0.91 0.91 0.88 0.883
Quick Ratio 0.57 0.61 0.54 0.57 0.53 0.52 0.52 0.52 0.50 0.50 0.51 0.56 0.50 0.54 0.50 0.50 0.52 0.44 0.48 0.49 0.489
Debt/Equity 4.06 5.65 -8.05 -8.19 -2.96 -2.38 -2.13 -1.75 -1.34 -1.37 -1.79 -1.75 -1.58 -2.54 -2.60 -3.36 -3.14 -3.13 -3.15 -3.45 -3.451
Net Debt/Equity 2.29 2.49 — — — — — — — — — — — — — — — — — — —
Debt/Assets 0.13 0.13 0.13 0.13 0.12 0.12 0.11 0.12 0.11 0.10 0.13 0.12 0.12 0.16 0.15 0.18 0.16 0.16 0.16 0.17 0.174
Debt/EBITDA 2.48 6.78 24.40 80.62 -26.47 8.34 3.65 3.64 3.72 2.50 3.47 2.87 2.01 2.91 2.55 3.01 2.77 2.79 2.95 2.86 2.860
Net Debt/EBITDA 1.40 2.98 14.16 15.11 -8.92 2.55 0.57 0.77 0.66 0.07 1.27 0.24 0.89 1.45 1.44 1.76 1.36 1.93 1.65 1.46 1.464
Interest Coverage 8.74 0.73 -2.91 -4.16 -6.67 -0.57 5.37 7.86 7.13 20.88 17.33 27.04 27.61 19.00 15.52 10.77 9.21 7.65 6.33 7.25 7.247
Equity Multiplier 30.86 43.77 -60.42 -61.89 -24.36 -20.10 -19.54 -14.65 -12.52 -13.50 -14.05 -14.04 -13.14 -15.71 -16.92 -19.10 -19.18 -20.14 -20.02 -19.87 -19.875
Cash Ratio snapshot only 0.111
Debt Service Coverage snapshot only 9.994
Cash to Debt snapshot only 0.488
FCF to Debt snapshot only 0.455
Defensive Interval snapshot only 951.7 days
Efficiency & Turnover
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Asset Turnover 3.95 3.88 4.11 4.11 4.33 4.38 4.65 4.70 4.82 4.75 4.94 5.12 5.17 4.75 4.64 4.53 4.77 4.65 4.70 4.61 4.605
Inventory Turnover 11.41 11.21 11.43 11.57 11.79 11.58 11.96 12.48 12.35 11.69 12.57 14.11 13.30 12.13 12.82 13.49 13.61 12.73 14.13 14.33 14.327
Receivables Turnover 18.66 18.89 18.64 18.45 18.38 18.53 18.70 18.92 18.84 18.62 19.54 19.55 19.46 18.39 18.33 17.58 18.34 18.78 19.04 18.79 18.794
Payables Turnover 7.13 6.87 7.18 6.88 6.97 6.80 7.06 6.94 6.78 6.49 6.91 7.11 7.00 6.54 6.60 6.45 6.72 6.70 6.83 6.70 6.698
DSO 20 19 20 20 20 20 20 19 19 20 19 19 19 20 20 21 20 19 19 19 19.4 days
DIO 32 33 32 32 31 32 31 29 30 31 29 26 27 30 28 27 27 29 26 25 25.5 days
DPO 51 53 51 53 52 54 52 53 54 56 53 51 52 56 55 57 54 54 53 54 54.5 days
Cash Conversion Cycle 0 -1 1 -2 -2 -2 -2 -4 -5 -5 -5 -7 -6 -6 -7 -9 -8 -6 -8 -10 -9.6 days
Fixed Asset Turnover snapshot only 63.214
Operating Cycle snapshot only 44.9 days
Cash Velocity snapshot only 52.357
Capital Intensity snapshot only 0.225
Growth (YoY)
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue 8.2% 9.5% 13.0% 11.6% 11.7% 12.7% 12.3% 13.0% 12.3% 11.9% 10.9% 10.6% 6.8% 2.8% 0.8% -1.8% 4.5% 10.1% 12.8% 14.2% 14.23%
Net Income 16.6% -59.8% -1.8% -2.5% -2.0% -3.3% 1.5% 1.3% 1.1% 1.5% 19.4% 2.3% 8.2% 1.1% 1.8% 83.0% 24.5% 26.9% 0.1% 9.8% 9.80%
EPS 18.3% -57.8% -1.9% -2.6% -2.0% -3.5% 1.5% 1.3% 1.1% 1.5% 25.8% 2.4% 8.4% 1.1% 1.9% 86.8% 27.6% 30.1% 2.2% 11.2% 11.19%
FCF -55.1% -62.6% -72.0% 34.8% 2.0% 1.5% 9.2% -13.8% -16.5% 21.6% -55.9% 37.7% -62.2% -1.1% 21.8% -43.0% 3.1% 12.2% 80.1% 1.4% 1.45%
EBITDA 13.2% -60.6% -88.7% -94.4% -1.1% -24.2% 4.6% 18.8% 7.3% 2.0% 30.2% 37.3% 1.0% 38.7% 78.7% 59.0% 26.9% 23.4% 0.3% 12.0% 11.98%
Op. Income 1.8% -85.1% -1.8% -2.3% -1.6% -1.4% 2.3% 2.2% 1.6% 28.5% 56.4% 71.9% 2.3% 60.2% 1.3% 82.0% 28.4% 33.7% 2.5% 14.9% 14.86%
OCF Growth snapshot only 1.16%
Asset Growth snapshot only 7.86%
Debt Growth snapshot only 6.45%
Shares Change snapshot only -1.25%
Dividend Growth snapshot only 0.65%
Growth (CAGR)
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue 3Y 6.3% 6.5% 7.2% 7.6% 8.2% 8.8% 9.0% 10.3% 10.7% 11.4% 12.1% 11.7% 10.3% 9.0% 7.9% 7.1% 7.8% 8.2% 8.0% 7.4% 7.44%
Revenue 5Y 5.9% 6.1% 6.6% 6.9% 7.4% 7.8% 8.1% 8.4% 8.5% 8.8% 9.0% 9.3% 8.7% 8.2% 7.7% 7.8% 8.7% 9.3% 9.9% 9.4% 9.37%
EPS 3Y 17.8% — — — — — — — -44.9% -17.9% -16.8% 18.6% 10.0% 39.9% — — — — 54.4% 91.6% 91.64%
EPS 5Y -1.4% -14.2% — — — — -19.7% 4.4% -25.4% — 2.0% -5.2% — — — — 15.0% 8.5% 11.0% 28.2% 28.24%
Net Income 3Y 15.6% — — — — — — — -47.7% -22.8% -21.7% 11.8% 4.1% 33.2% — — — — 49.9% 87.3% 87.27%
Net Income 5Y -3.5% -16.3% — — — — -22.9% 0.3% -28.3% — 1.8% -8.9% — — — — 10.4% 3.8% 6.3% 22.9% 22.91%
EBITDA 3Y 10.1% -21.9% -48.1% -71.3% — — — — -14.5% -3.6% -6.0% 15.0% 4.1% 46.5% 1.4% 2.5% — 72.4% 32.7% 34.7% 34.70%
EBITDA 5Y -5.7% -22.7% -40.2% -52.1% — -24.7% -13.2% 4.6% -5.9% 1.6% 0.5% -8.5% — — — — 10.2% 8.9% 8.3% 22.0% 22.02%
Gross Profit 3Y -2.2% -2.4% -2.4% -1.4% -1.6% -1.3% -1.4% 0.1% 0.5% 1.1% 2.2% 2.9% 4.0% 5.3% 6.8% 7.7% 9.6% 10.5% 11.5% 12.4% 12.37%
Gross Profit 5Y 0.5% -0.0% -0.5% 0.0% -0.3% -0.9% -1.2% -0.8% -0.4% 0.4% 1.3% 1.5% 1.9% 2.2% 2.4% 3.5% 4.5% 4.9% 6.0% 7.6% 7.60%
Op. Income 3Y 30.4% -49.7% — — — — — — 1.0% 20.9% 19.1% 38.4% 7.0% 1.7% — — — — 54.6% 53.2% 53.18%
Op. Income 5Y -8.6% -46.8% — — — — -17.6% 41.8% -3.9% 8.5% 7.8% -9.5% — — — — 34.4% 30.5% 31.9% 40.8% 40.81%
FCF 3Y -10.7% -13.1% -43.2% 4.5% 35.7% 18.7% 34.9% 14.2% 4.3% 4.2% 7.9% 17.0% -1.5% — 76.2% -12.2% 9.4% 25.4% -1.1% 24.3% 24.27%
FCF 5Y -15.7% -8.1% -6.6% 28.0% 12.3% 11.2% 11.8% -0.2% 12.5% 14.7% -3.9% 6.3% -4.7% — 5.7% 3.1% 12.2% 12.9% 22.5% 17.4% 17.40%
OCF 3Y -8.1% -10.0% -34.0% 4.7% 30.5% 16.3% 30.7% 13.1% 5.1% 4.9% 8.2% 15.6% 1.5% -87.4% 54.8% -8.4% 9.8% 24.1% 0.2% 22.1% 22.15%
OCF 5Y -13.5% -7.6% -6.3% 21.4% 10.9% 10.0% 11.1% 0.5% 11.4% 13.9% -1.7% 6.7% -1.5% -72.8% 5.8% 4.1% 11.7% 12.4% 20.1% 16.3% 16.33%
Assets 3Y 2.4% 2.6% 1.1% 2.3% 3.5% 2.7% 1.8% 2.1% 1.6% 1.4% 1.5% 0.5% 0.1% 2.5% 5.8% 6.6% 8.4% 9.3% 9.3% 9.7% 9.75%
Assets 5Y 4.6% 4.5% 4.3% 1.8% 0.7% 0.7% 1.1% 1.6% 1.8% 2.9% 2.4% 2.0% 1.9% 2.7% 3.9% 5.4% 5.8% 5.4% 5.3% 5.2% 5.21%
Equity 3Y -38.2% -45.1% — — — — — — — — — — — — — — — — — — —
Book Value 3Y -37.1% -43.9% — — — — — — — — — — — — — — — — — — —
Dividend 3Y 2.3% 2.3% 2.4% 2.1% 1.3% 2.1% 2.4% 2.8% 3.0% 4.1% 4.2% 4.4% 4.4% 3.9% 4.0% 4.3% 4.5% 3.3% 2.7% 2.1% 2.13%
Growth Quality
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue Stability 0.99 0.98 0.95 0.96 0.96 0.94 0.92 0.93 0.94 0.93 0.94 0.95 0.97 0.97 0.96 0.94 0.99 0.99 0.97 0.94 0.941
Earnings Stability 0.03 0.05 0.18 0.18 0.01 0.04 0.01 0.01 0.03 0.09 0.16 0.05 0.33 0.34 0.51 0.64 0.07 0.08 0.30 0.57 0.567
Margin Stability 0.89 0.89 0.88 0.88 0.86 0.84 0.82 0.82 0.82 0.82 0.83 0.84 0.85 0.86 0.87 0.87 0.87 0.87 0.88 0.90 0.899
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 0.50 0.500
Earn. Growth Consistency 1.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
FCF Positive Streak 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 1 1 1
Earnings Persistence 0.50 0.50 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.50 0.50 0.50 0.50 0.50 0.50 0.90 0.89 1.00 0.96 0.961
Earnings Smoothness 0.85 0.15 — — — — — — — — 0.82 0.00 0.00 0.31 0.05 0.41 0.78 0.76 1.00 0.91 0.907
ROE Trend 2.78 2.31 — — — — — — — — — — — — — — — — — — —
Gross Margin Trend -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.004
FCF Margin Trend -0.01 -0.01 -0.01 0.00 0.01 0.00 0.02 -0.00 0.00 0.01 -0.00 0.00 -0.01 -0.02 -0.01 -0.00 0.01 0.02 0.01 0.01 0.006
Sustainable Growth Rate 39.7% -1.2% — — — — — — — — — — — — — — — — — — —
Internal Growth Rate 1.3% — — — — — — — — 0.3% 0.1% 0.8% 1.8% 1.8% 2.3% 2.2% 2.3% 2.3% 2.0% 2.3% 2.27%
Cash Flow Quality
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
OCF/Net Income 1.33 2.69 -0.83 -3.35 -3.47 -2.51 10.74 10.88 24.06 6.16 4.59 4.40 1.23 0.00 1.89 1.54 3.15 3.66 3.21 3.02 3.019
FCF/OCF 0.74 0.75 0.56 0.88 0.90 0.87 0.91 0.83 0.85 0.86 0.79 0.86 0.68 -163.67 0.83 0.77 0.89 0.90 0.88 0.87 0.875
FCF/Net Income snapshot only 2.640
OCF/EBITDA snapshot only 1.488
CapEx/Revenue 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.3% 0.26%
CapEx/Depreciation snapshot only 0.679
Accruals Ratio -0.01 -0.02 -0.04 -0.09 -0.11 -0.10 -0.11 -0.06 -0.07 -0.07 -0.04 -0.07 -0.01 0.03 -0.03 -0.02 -0.07 -0.08 -0.06 -0.06 -0.063
Sloan Accruals snapshot only -0.065
Cash Flow Adequacy snapshot only 4.539
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Dividend Yield 4.4% 4.3% 3.9% 4.2% 3.2% 2.8% 2.9% 2.3% 2.5% 2.1% 1.9% 2.1% 1.9% 1.7% 1.5% 1.2% 1.3% 1.0% 1.0% 0.9% 0.90%
Dividend/Share $1.99 $2.04 $2.06 $2.03 $2.02 $2.07 $2.07 $2.07 $2.06 $2.07 $2.05 $2.04 $2.02 $2.03 $2.06 $2.06 $2.07 $2.09 $2.08 $2.07 $2.05
Payout Ratio 50.7% 1.0% — — — — 1.2% 2.0% 3.7% 79.9% 91.0% 58.5% 38.7% 37.6% 31.8% 31.6% 31.0% 29.7% 31.5% 28.6% 28.65%
FCF Payout Ratio 51.2% 51.0% 1.3% 20.4% 16.2% 19.4% 11.7% 22.3% 18.1% 15.0% 25.1% 15.4% 46.2% — 20.3% 26.7% 11.1% 9.0% 11.2% 10.9% 10.85%
Total Payout Ratio 1.1% 2.8% — — — — 4.4% 9.7% 14.5% 3.2% 3.2% 1.5% 87.5% 67.3% 80.9% 31.6% 31.0% 51.8% 47.1% 1.1% 1.08%
Div. Increase Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Chowder Number 0.06 0.05 0.03 0.02 -0.01 -0.03 -0.03 -0.04 -0.04 -0.04 -0.04 -0.03 -0.02 -0.01 0.00 0.00 0.01 0.01 -0.00 0.00 0.003
Buyback Yield 5.4% 7.5% 6.9% 7.4% 8.7% 7.6% 8.0% 8.7% 7.2% 6.2% 4.7% 3.2% 2.4% 1.4% 2.3% 0.0% 0.0% 0.8% 0.5% 2.4% 2.42%
Net Buyback Yield 5.4% 7.5% 6.9% 7.4% 8.7% 7.6% 8.0% 8.7% 7.2% 6.2% 4.7% 3.2% 2.4% 1.4% 2.3% 0.0% 0.0% 0.8% 0.5% 2.4% 2.42%
Total Shareholder Return 9.8% 11.8% 10.8% 11.5% 11.9% 10.4% 10.9% 10.9% 9.7% 8.3% 6.5% 5.3% 4.2% 3.1% 3.8% 1.2% 1.3% 1.8% 1.5% 3.3% 3.29%
DuPont Factors
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Tax Burden (NI/EBT) 0.84 -12.33 1.53 1.21 1.06 6.62 0.95 0.41 0.29 0.56 0.59 0.71 0.72 0.73 0.74 0.74 0.74 0.73 0.78 0.79 0.788
Interest Burden (EBT/EBIT) 0.89 -0.37 1.34 1.24 1.15 2.74 0.81 0.87 0.86 0.95 0.94 0.97 0.97 0.95 0.94 0.91 0.89 0.94 0.92 0.86 0.862
EBIT Margin 0.01 0.00 -0.00 -0.00 -0.00 -0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.010
Asset Turnover 3.95 3.88 4.11 4.11 4.33 4.38 4.65 4.70 4.82 4.75 4.94 5.12 5.17 4.75 4.64 4.53 4.77 4.65 4.70 4.61 4.605
Equity Multiplier 30.10 29.77 78.67 81.64 -222.63 -72.56 -29.31 -23.79 -16.52 -16.08 -16.27 -14.34 -12.82 -14.53 -15.41 -16.39 -15.97 -17.89 -18.44 -19.50 -19.495
Per Share
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
EPS (Diluted TTM) $3.93 $1.98 $-3.47 $-3.39 $-4.00 $-4.87 $1.79 $1.03 $0.56 $2.59 $2.26 $3.48 $5.23 $5.40 $6.46 $6.50 $6.67 $7.03 $6.61 $7.23 $7.23
Book Value/Share $4.82 $3.55 $-2.53 $-2.58 $-6.52 $-8.48 $-8.60 $-11.65 $-13.96 $-14.02 $-13.33 $-13.11 $-13.38 $-12.31 $-12.23 $-11.59 $-12.05 $-12.17 $-12.00 $-12.16 $-11.54
Tangible Book/Share $-29.80 $-27.05 $-31.71 $-30.32 $-33.51 $-33.84 $-34.06 $-35.60 $-35.69 $-35.85 $-39.89 $-39.44 $-39.45 $-42.91 $-57.93 $-62.33 $-62.72 $-71.15 $-70.04 $-69.68 $-69.68
Revenue/Share $579.13 $609.56 $643.08 $659.51 $684.98 $739.51 $770.01 $807.13 $840.24 $878.18 $899.64 $925.18 $915.49 $914.06 $921.69 $927.41 $980.38 $1031.59 $1061.65 $1072.78 $1077.32
FCF/Share $3.89 $4.00 $1.62 $9.95 $12.46 $10.70 $17.62 $9.28 $11.36 $13.80 $8.18 $13.25 $4.38 $-2.02 $10.12 $7.71 $18.63 $23.23 $18.61 $19.09 $19.17
OCF/Share $5.24 $5.31 $2.89 $11.35 $13.89 $12.23 $19.28 $11.18 $13.38 $15.96 $10.36 $15.33 $6.46 $0.01 $12.23 $9.99 $20.99 $25.75 $21.22 $21.83 $21.92
Cash/Share $8.52 $11.25 $8.57 $17.15 $12.79 $14.00 $15.47 $16.05 $15.42 $18.66 $15.18 $20.95 $11.70 $15.68 $13.80 $16.14 $19.22 $11.72 $16.68 $20.49 $20.58
EBITDA/Share $7.88 $2.96 $0.84 $0.26 $-0.73 $2.42 $5.02 $5.60 $5.02 $7.67 $6.89 $7.98 $10.49 $10.77 $12.52 $12.94 $13.65 $13.63 $12.82 $14.68 $14.68
Debt/Share $19.56 $20.08 $20.41 $21.11 $19.29 $20.16 $18.35 $20.38 $18.71 $19.20 $23.89 $22.89 $21.08 $31.30 $31.86 $38.94 $37.79 $38.09 $37.78 $41.97 $41.97
Net Debt/Share $11.04 $8.83 $11.84 $3.96 $6.50 $6.16 $2.88 $4.33 $3.30 $0.54 $8.72 $1.94 $9.38 $15.62 $18.06 $22.80 $18.57 $26.37 $21.10 $21.49 $21.49
Per Employee
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Employee Count snapshot only 63,900
Revenue/Employee snapshot only $3978841.94
Income/Employee snapshot only $26823.16
EBITDA/Employee snapshot only $54428.79
FCF/Employee snapshot only $70813.77
Assets/Employee snapshot only $896697.97
Market Cap/Employee snapshot only $879162.44
Academic Models
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 5.085
Altman Z-Prime snapshot only 0.803
Piotroski F-Score 7 6 5 5 5 5 7 8 7 7 6 6 7 7 6 6 6 6 6 8 8
Beneish M-Score -2.38 -2.48 -2.46 -2.84 -2.85 -2.78 -2.92 -2.77 -2.86 -2.82 -2.63 -2.60 -2.49 -2.22 -2.34 -2.32 -2.36 -2.45 -2.66 -2.80 -2.796
Ohlson O-Score snapshot only -6.844
Net-Net WC snapshot only $-89.75
EVA snapshot only $1828393928.24
Credit
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Credit Rating snapshot only B-
Credit Score 66.84 43.40 38.55 49.01 63.94 55.62 78.78 77.66 81.35 89.18 82.26 89.17 74.06 68.36 78.41 20.00 20.00 20.00 20.00 20.00 20.000
Credit Grade snapshot only 16
Credit Trend snapshot only 0.000
Implied Spread (bps) snapshot only 900.000
Industry Credit Rank snapshot only 88
Sector Credit Rank snapshot only 78

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms